real-world data

In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.
Robin T Zon, MD, FACP, FASCO, and Bobby Daly, MD, MBA, discuss ASCO's recently published results of an evaluation of national pathway vendors against the Criteria for High-Quality Clinical Pathways.
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
The National Comprehensive Cancer Network has released the first-ever clinical practice guidelines addressing patients living with HIV who are diagnosed with cancer to help them receive safe and necessary treatment.
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
A recent study evaluated health care utilization and costs of pulmonary arterial hypertension in a real-world setting by comparing periods before and after treatment initiation.
A study presented at the ASCO Cancer Survivorship Symposium evaluated the impact of a breast cancer survivorship model on health system resources and costs.
A recent study found a link between HbA1C levels, diabetes status, and long-term cognitive decline.
John Danaher, MD, President of Clinical Solutions, Elsevier, and Kathy Lokay, President and CEO, Via Oncology, speak on behalf of their respective companies regarding Elsevier's recent acquisition of Via Oncology.
Despite a trend toward increased metric use, approximately 50% of patients with RA are not routinely assessed with a disease activity metric, according to the results of a recent survey.